Skip to main content
NovartisRecognition

Novartis ranks first place in 2026 Access to Medicine Index

Source: Autobound Signal API · 77 signals tracked for Novartis · updated

Get Novartis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Novartis this week? Use Autobound signals for novartis.com.

What happened

Novartis ranked first place in the 2026 Access to Medicine Index published by the Access to Medicine Foundation.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Basel, November 10, 2026 – Novartis today announced the company has ranked first place in the 2026 Access to Medicine Index. Published every two years, the Index is an independent assessment of how major research-based pharmaceutical companies are improving access to medicines. "Being ranked first in the Access to Medicine Index for the second consecutive time is an honor, and a recognition of our continued efforts to expand access to healthcare together with our partners," said Vas Narasimhan, CEO of Novartis. "We remain committed to transforming scientific progress into meaningful impact for more patients around the world." The ranking retains Novartis' leading position in the Index since 2024, with the company scoring an overall 3.86 out of five in 2026. Novartis also ranked first across all individual Technical Areas assessed, the only company to do so since the Index was first published in 2008, including a score for R&D almost twice the sector average. The Index is published by the Access to Medicine Foundation, an independent non-profit organization, which assesses 20 of the world's largest research-based pharmaceutical companies on their efforts to improve access to medicines, vaccines and diagnostics across 84 diseases across 113 low- and middle-income countries.¹ Companies were assessed on three Technical Areas in 2026: Governance of Access, which scores how...

Keep reading with a free account

The rest of this article, and every signal for Novartis, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Recognition

What this signalsAnalyst or press recognition often comes during a period of growth.

Recognition
first place in the 2026 Access to Medicine Index
Takes effect
Nov 10, 2026
Location
Basel, Basel-Stadt, Switzerland

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Nov 10, 2026
signal_type
news
signal_subtype
recognized_as

Use this data

Get every recognition signal for Novartis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novartis this week?”

  2. Send it to your own tools

    The Signal API returns recognition signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/06b7ecee-8c57-45db-60e9-7210b80bc190 returns this record as JSON. POST /v1/companies/enrich returns every signal for novartis.com.

{
  "signal_id": "06b7ecee-8c57-45db-60e9-7210b80bc190",
  "signal_type": "news",
  "signal_subtype": "recognized_as",
  "detected_at": "2026-11-10T13:00:00+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/11/10/3399390/0/en/novartis-ranks-first-place-in-2026-access-to-medicine-index.html",
    "title": "Novartis ranks first place in 2026 Access to Medicine Index",
    "excerpt": "Basel, November 10, 2026 – Novartis today announced the company has ranked first place in the 2026 Access to Medicine Index. Published every two years, the Index is an independent assessment of how major research-based pharmaceutical companies are improving access to medicines. “Being ranked first in the Access to Medicine Index for the second consecutive time is an honor, and a recognition of our continued efforts to expand access to healthcare together with our partners,” said Vas Narasimhan, CEO of Novartis. “We remain committed to transforming scientific progress into meaningful impact for more patients around the world.” The ranking retains Novartis’ leading position in the Index since 2024, with the company scoring an overall 3.86 out of five in 2026. Novartis also ranked first across all individual Technical Areas assessed, the only company to do so since the Index was first published in 2008, including a score for R&D almost twice the sector average. The Index is published by the Access to Medicine Foundation, an independent non-profit organization, which assesses 20 of the world’s largest research-based pharmaceutical companies on their efforts to improve access to medicines, vaccines and diagnostics across 84 diseases across 113 low- and middle-income countries.¹ Companies were assessed on three Technical Areas in 2026: Governance of Access, which scores how...",
    "summary": "Novartis ranked first place in the 2026 Access to Medicine Index published by the Access to Medicine Foundation.",
    "location": "Basel, Switzerland",
    "planning": false,
    "confidence": 0.95,
    "recognition": "first place in the 2026 Access to Medicine Index",
    "published_at": "2026-11-10T13:00:00Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-Stadt",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-10",
    "article_sentence": "Novartis today announced the company has ranked first place in the 2026 Access to Medicine Index."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.